Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Colorectal Cancer: Update Bulletin [August 2014]

Product Code:
596200298
Release Date:
August 2014
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Colorectal Cancer: ASCO 2014, Vectibix, metastatic CRC (mCRC), ASPECCT, CALGB 80405 study results, TAS-102

Highlights from this event update bulletin

  • Vectibix’s approval in the first-line setting unlikely to change prescribing habits significantly
  • Data from the CALGB 80405 study reinforces status quo, but all-RAS analysis ongoing
  • Less enthusiasm for EGFR inhibitors in potentially resectable disease
  • TAS-102 poised to position itself ahead of Stivarga in heavily pre-treated patients

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved